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Successful Treatment with Fusidic Acid in a Patient 
with Folliculitis Decalvans
Dear Editor,
Folliculitis decalvans (FD) is a rare form of prima-
ry neutrophilic cicatricial alopecia. It is a highly dis-
tressing disease that affects young and middle-aged 
adults, with a slight male predominance (1).
The most frequent clinical manifestations are folli-
cular pustules and diffuse and perifollicular erythema 
that heal with centrifugal scarring. Follicular tufting, 
erosions, and hemorrhagic crusts can also be present, 
and this alopecia is most often located at the ver-
tex and occipital area. Patients frequently complain 
about pain, itching, or burning sensations, and the 
involvement of other body areas is rare (2).
The pathogenesis of this disease remains unclear. 
Staphylococcus aureus and other hair follicle bacteria 
can often be isolated from the pustules, suggesting 
the role of a bacterial infection in its etiology. A defect 
in the host’s immune response can also be postula-
ted by reports of familial cases and the appearance 
of FD in patients with immunity dysfunctions. Other 
mechanical factors have been suggested, such as 
structural abnormalities of the follicle or local inflam-
mation (2).
Management of this alopecia is difficult and its 
course is typically chronic and relapsing. The treat-
ment aim is to stop inflammation and further irrever-
sible destruction of hair follicles. Antibiotics remain 
the first-line therapy, due both to their anti-inflamma-
tory and antimicrobial properties (1). Although topi-
cal fusidic acid is widely used as adjuvant treatment, 
there are few data regarding its oral use. 
We report a case of folliculitis decalvans success-
fully treated with oral fusidic acid. Our patient was a 
41-year old Cape Verdean woman with a two month 
history of alopecia with painful, purulent discharge 
at the vertex of the scalp. The patient was diagnosed 
with human immunodeficiency virus type 1 (HIV-1) 
infection 5 years prior and was stable on her regimen 
of efavirenz, tenofovir, and emtricitabine, with unde-
tectable viral load. She denied application of topical 
or capillary products. Dermatological examination re-
vealed a patch of cicatricial alopecia with crusts and 
follicular pustules (Figure 1). Direct microscopic exa-
mination and mycological culture showed no fungal 
element. A diagnosis of folliculitis decalvans was es-
tablished and the patient was started on oral fusidic 
acid at a dose of 500 mg three times a day. Betame-
thasone dipropionate 0.05% and salicylic acid 3% lo-
tion as well as azelaic acid 5% lotion were also applied 
to the affected area once daily. After two months of 
treatment, the patient showed clinical improvement, 
with less erythema and suppuration of the affected 
scalp. A partial hair regrowth was noted, mainly at the 
periphery. Subsequently the patient maintained only 
topical therapy, and no recurrences were observed 
after 6-months of follow-up. 
Fusidic acid is useful in the treatment of skin and 
soft tissue infections, particularly those due to S. au-
reus, as shown by randomized controlled studies (3). 
The clinical efficacy of fusidic acid in the treatment of 
folliculitis decalvans has been reported previously. 
Bogg was the first to describe this useful effect (4). 
Sutter also reported good results with fusidic acid 
used both topically and orally (500 mg three times a 
day) (5). However, both failed to report the treatment 
duration or the outcome on discontinuation. Abeck 
described three patients that responded to a three 
Figure 1. Large atrophic alopecic patch at the occipital re-
gion with areas of follicular tufting and peripheral crusts.
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week oral course of fusidic acid (500 mg three times a 
day) and to a maintenance treatment with zinc sulfa-
te (4). During the following year, recurrence was ob-
served in only one patient after ending zinc sulfate 
therapy.
Oral antibiotics are frequently used to treat follicu-
litis decalvans. Tetracyclines and the combination of 
clindamycin with rifampicin are the most common-
ly used (2). However, the disease usually progresses 
when treatment is stopped. Fusidic acid is an anti-sta-
phylococcal drug with few adverse effects. It is highly 
bioavailable orally, and has a long plasma half-life. 
Despite years of clinical use in numerous countries, 
resistance rates remain at low levels to date (6). Sin-
ce clinical series or cases including ours have sho-
wn good results, this drug should not be forgotten 
when considering treatment options for folliculitis 
decalvans.
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